Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Lake Street Initiates Coverage On Cellebrite DI with Buy Rating, Announces Price Target of $13

Author: Benzinga Newsdesk | April 19, 2024 12:05pm
Lake Street analyst Frank Takkinen initiates coverage on Cellebrite DI (NASDAQ:CLBT) with a Buy rating and announces Price Target of $13.

Posted In: CLBT

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist